Results 261 to 270 of about 103,365 (348)

Glucagon-like peptide-1 receptor agonists as potential preventive and therapeutic agents in ischemic stroke

Muhammad Ali, Meng Yang, Sarah Eide, Hong‐Shuo Sun, Tianru Jin, Zhong‐Ping Feng   +5 more
openalex   +1 more source

Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER)

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To assess the real‐world effectiveness of semaglutide versus tirzepatide in reducing major adverse cardiovascular events (MACE) among patients with overweight/obesity and established atherosclerotic cardiovascular disease (ASCVD) without diabetes in an insured US population.
Lauren Wilson, Zhenxiang Zhao, Victoria Divino, Matthew Bassan, Bríain Ó. Hartaigh, Signe Stensen, Kerem Ozer   +6 more
wiley   +1 more source

Eloralintide, a selective, long‐acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Eloralintide (LY3841136) is a potent, long‐acting selective amylin receptor agonist currently under development for the treatment of obesity with once‐weekly subcutaneous dosing. Materials and Methods This 12‐week Phase 1, randomised, placebo‐controlled, participant‐ and investigator‐blinded, multiple ascending dose study evaluated the ...
Shobha Bhattachar, Lai San Tham, Beth Tidemann‐Miller, Hilda Ibriga, Hongchang Qu, Daniel A. Briere, Axel Haupt, Kieren J. Mather, Edward Pratt   +8 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea. [PDF]

Curr Opin Pulm Med
D'Annibale DA, Mimoto M, McCowen KC, Malhotra A.   +3 more
europepmc   +1 more source

Glucagon-like peptide-1 receptor analog use is associated with reduced thromboembolic events compared with dipeptidyl peptidase-4 inhibitors in rheumatoid arthritis patients: A global retrospective cohort study [PDF]

Qi Wang, Donald D. Anthony
openalex   +1 more source

Dual action of imeglimin on insulin secretion and sensitivity in type 2 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Imeglimin is a novel oral hypoglycemic agent approved for the treatment of type 2 diabetes in Japan, with dual actions to enhance insulin secretion and improve insulin sensitivity, suggested by preclinical evidence. However, the effect of imeglimin on tissue‐specific insulin sensitivity and glucose kinetics using glucose tracers is ...
Tsubasa Tajima, Hideyoshi Kaga, Naoaki Ito, Toshiki Kogai, Hitoshi Naito, Saori Kakehi, Satoshi Kadowaki, Yuya Nishida, Ryuzo Kawamori, Yoshifumi Tamura, Hirotaka Watada   +10 more
wiley   +1 more source

Improved cardiovascular outcomes with glucagon-like peptide-1 receptor agonists - what is the role of weight reduction? [PDF]

Cardiovasc Endocrinol Metab
Jacob S, Eckel RH, Krentz AJ.
europepmc   +1 more source

Regulation of glucose kinetics during exercise by the glucagon‐like peptide‐1 receptor

, 2012
Melissa A. Burmeister, D. P. Bracy, Freyja D. James, Rochelle M. Holt, Julio E. Ayala, Emily King, David H. Wasserman, Daniel J. Drucker, Julio E. Ayala   +8 more
openalex   +2 more sources

GLP‐1 receptor agonists and cardiovascular outcomes in Asian, Black or African American, and White populations: An updated meta‐analysis including the SOUL trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate the cardiovascular efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) in Asian, Black or African American, and White populations, and to assess whether the magnitude of cardiovascular risk reduction differs across these populations.
Masashi Hasebe, Chen‐Yang Su, Hisashi Kamido, Daisuke Yabe, Satoshi Yoshiji   +4 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders. [PDF]

J Neurol Neurosurg Psychiatry
De Giorgi R, Ghenciulescu A, Yotter C, Taquet M, Koychev I.   +4 more
europepmc   +1 more source